Georgia SB 220 Signed: Medical Cannabis Expansion Removes THC Cap

Georgia just took its biggest step forward in medical cannabis history. On May 13, 2026, Governor Brian Kemp signed Senate Bill 220 into law, transforming one of the most restrictive medical cannabis programs in the country into a framework that actually gives patients meaningful access to the medicine they need.

The legislation, formally known as the Putting Georgia's Patients First Act, eliminates the previous five percent THC potency cap that had long frustrated patients and advocates. In its place, the new law establishes a legal possession limit of 12,000 milligrams of cumulative THC for registered patients, opening the door to full-strength medical cannabis products for the first time in the state's history.

What Changes Under the Putting Georgia's Patients First Act

The scope of SB 220 is sweeping. Beyond removing the THC cap, the law introduces entirely new product categories, expands the list of qualifying medical conditions, and replaces outdated terminology that had defined the program since its inception.

Product Expansion and New Consumption Methods

For the first time in Georgia, registered patients can now legally purchase edibles, gummies, and vaporized flower. The inclusion of vaporization is a particularly significant development, though the law specifies that the option is limited to individuals aged 21 and older. Notably, smoking or burning medical cannabis remains prohibited under SB 220, drawing a careful line between vaporization technology and traditional combustion methods.

The distinction matters from both a public health and political perspective. By permitting vaporization while maintaining the ban on smoking, Georgia lawmakers crafted a compromise that expands patient access while addressing concerns about secondhand smoke and public perception.

Expanded Qualifying Conditions

SB 220 takes a notably patient-centered approach to qualifying conditions. The legislation removes previous qualifications about "severe" and "end-stage" limitations for many illnesses, broadening access for patients who may benefit from cannabis therapy at earlier stages of their conditions.

New qualifying conditions added under SB 220 include lupus, autism, Stage III HIV, severe Alzheimer's disease, and inflammatory bowel disease. These additions bring Georgia's qualifying conditions list more in line with states that have long recognized the therapeutic potential of cannabis for a wider range of medical needs.

A New Name for a New Era

In a symbolic but meaningful change, SB 220 replaces the term "low THC oil" with "medical cannabis" throughout state law. The rebranding signals a deliberate shift in how Georgia frames its program, moving from a narrow focus on THC content to a broader recognition of cannabis as a legitimate medical treatment.

The Political Landscape Behind SB 220

Governor Kemp's signing of SB 220 came on the final day he could have vetoed the legislation, adding a layer of political suspense to what had been a long legislative journey. In his public comments, Kemp acknowledged his personal reservations about recreational cannabis legalization while maintaining that a well-implemented medical program does not have to lead inevitably to recreational markets.

The bill's passage through both chambers of the Georgia legislature demonstrated bipartisan support for medical cannabis reform. The legislation navigated committee hurdles and floor votes with enough momentum to reach the governor's desk despite lingering opposition from some conservative lawmakers who viewed any expansion as a step toward full legalization.

Georgia Joins an Expanding Medical Cannabis Landscape

With the signing of SB 220, NORML now classifies Georgia as the 41st medical cannabis state in the nation, a milestone that reflects how dramatically the national landscape has shifted over the past decade. Georgia's expansion comes at a time when federal rescheduling of cannabis to Schedule III is already reshaping the regulatory environment across the country.

The timing is not coincidental. Following the Department of Justice's April 23 order moving state-licensed medical cannabis to Schedule III, states across the country are reassessing their programs and expanding patient access. Georgia's SB 220 fits squarely within this national trend of modernizing medical cannabis frameworks to align with emerging federal recognition of cannabis as a legitimate therapeutic tool.

What This Means for Georgia Patients

For the estimated 30,000 patients currently registered in Georgia's medical cannabis program, SB 220 represents a transformative change. Patients who previously had access only to low-THC oil products will now be able to work with their physicians to explore a full range of medical cannabis options, including higher-potency products that research suggests may be more effective for managing chronic pain, spasticity, and other qualifying conditions.

The expanded product menu also has practical implications for the state's licensed operators. Companies that have been manufacturing and dispensing low-THC oil will need to adapt their operations to produce and stock the new product categories permitted under SB 220, including edibles, gummies, and vaporizable flower.

Patient Access and Dispensary Infrastructure

Georgia's dispensary infrastructure has been a persistent bottleneck in the state's medical cannabis program. While SB 220 does not directly address the number of licensed dispensaries, the expanded product categories and higher THC limits are expected to drive increased patient enrollment, which could in turn create pressure for further infrastructure development.

Advocates have noted that geographic access remains uneven across the state, with rural patients often traveling significant distances to reach a licensed dispensary. As the program grows under SB 220, the question of whether Georgia needs more dispensary licenses will likely become a central point of legislative debate.

A Cautious Model for the Deep South

Georgia's approach to medical cannabis expansion offers a template for other states in the Deep South that are considering their own reforms. By maintaining the ban on smoking while permitting vaporization, restricting vaping to adults 21 and over, and rejecting recreational legalization, SB 220 charts a middle path that may prove palatable to conservative-leaning legislatures in neighboring states.

Alabama, Mississippi, and Tennessee have all seen various forms of medical cannabis legislation in recent years, and Georgia's SB 220 may serve as a reference point for lawmakers in those states who are navigating similar political dynamics.

Looking Ahead

The true test of SB 220 will come in its implementation. State regulators will need to develop rules governing the new product categories, establish testing standards for higher-potency products, and ensure that the expanded program maintains the safety and compliance frameworks that protect patients and communities.

For now, Georgia's patients and advocates are marking a hard-won victory. After years of operating under one of the most restrictive medical cannabis frameworks in the country, the Putting Georgia's Patients First Act delivers the kind of meaningful reform that can make a real difference in patients' lives. Whether it also becomes a stepping stone toward broader cannabis reform in Georgia remains a question for future legislatures to answer.

Looking for a verified shop carrying products like these? Browse Budpedia's dispensary near me directory to find licensed cannabis retailers in your state with up-to-date menus.